Influence of immunosuppressive therapy on the state of immune protection in children
DOI:
https://doi.org/10.15574/SP.2024.6(142).2026Keywords:
immunosuppressive therapy, lymphocyte subpopulations, serum immunoglobulins, vaccination, childrenAbstract
For the treatment of rheumatological diseases, autoimmune lymphoproliferative syndrome and nephrotic syndrome in children, glucocorticosteroid therapy with/without cytostatics is used. Immunosuppression is a serious side effect of these medications.
Aim - to investigate immunological parameters in children receiving immunosuppressive therapy in order to determine vaccination tactics.
Materials and methods. 50 healthy children (comparison group) and 34 children who received immunosuppressive therapy for rheumatological pathology, autoimmune lymphoproliferative syndrome or nephrotic syndrome (study group) participated in the study. Patients who received high-dose immunosuppressive therapy (n=16) made up the subgroup I, low-dose immunosuppressive therapy (n=18) - the subgroup II. Determination of subpopulations of blood lymphocytes was carried out by the method of flow cytometry, serum immunoglobulins - by the method of radial immunodiffusion. Statistical analysis was performed using the SPSS 23.0 software package.
Results. In children who received immunosuppressive therapy, a significant increase in the number of T-lymphocytes (CD3+), a decrease in B-lymphocytes (CD19+) and NK cells (CD3-CD16/56+) was established, while the average levels of serum IgA, IgM, IgG did not differ from the indicators of healthy children, which demonstrates the preservation of humoral immunity. However, in children who received high-dose immunosuppressive therapy, a dose-dependent decrease in the level of serum IgA, IgM, and IgG was found, respectively, by 1.7, 1.3 times, and by 18.9%.
Conclusions. It is advisable to vaccinate children before starting immunosuppressive therapy for rheumatological pathology or nephrotic syndrome.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
References
Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG et al. (2016). The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 18(1): 210. https://doi.org/10.1186/s13075-016-1109-8; PMid:27655411 PMCid:PMC5032246
Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG et al. (2012). Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 64(8): 2773-2780. https://doi.org/10.1002/art.34458; PMid:22569881 PMCid:PMC3409300
Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D et al. (2020). Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care Res (Hoboken). 72(10): 1420-1430. https://doi.org/10.1002/acr.24044; PMid:31421019 PMCid:PMC7589221
Hamad Saied M, van Straalen JW, de Roock S, de Joode-Smink GCJ, Verduyn Lunel FM, Swart JF et al. (2023). Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis. Vaccine. 41(37): 5477-5482. https://doi.org/10.1016/j.vaccine.2023.07.052; PMid:37516575
Horneff G, Minden K, Rolland C, Daly ACH, Borlenghi C, Ruperto N. (2023). Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J. 21(1): 20. https://doi.org/10.1186/s12969-023-00798-8; PMid:36829225 PMCid:PMC9951426
Hurd A, Beukelman T. (2013). Infectious complications in juvenile idiopathic arthritis. Curr Rheumatol Rep. 15(5): 327. https://doi.org/10.1007/s11926-013-0327-1; PMid:23529583
Lisovska AM, Volokha AP, Bondarenko AV, Marushko TV, Golubovskaya YuE. (2020). State of protection against polio in children, who receive immunosuppressive therapy. Modern pediatrics (Ukraine). 3(107): 29-32. https://doi.org/10.15574/SP.2020.107.29
Marasco E, Aquilani A, Cascioli S, Moneta GM, Caiello I, Farroni C et al. (2018). Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 70(4): 606-615. https://doi.org/10.1002/art.40410; PMid:29316374
Matson DR, Yang DT. (2020). Autoimmune Lymphoproliferative Syndrome: An Overview. Arch Pathol Lab Med. 144(2): 245-251. https://doi.org/10.5858/arpa.2018-0190-RS; PMid:30958694 PMCid:PMC10415410
Nagy A, Mátrai P, Hegyi P, Alizadeh H, Bajor J, Czopf L et al. (2019). The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis. Pediatr Rheumatol Online J. 17(1): 4. https://doi.org/10.1186/s12969-019-0305-x; PMid:30658717 PMCid:PMC6339290
Nagy A, Mosdosi B, Simon D, Dergez T, Berki T. (2020). Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study. Front Pediatr. 8: 614354. https://doi.org/10.3389/fped.2020.614354; PMid:33363071 PMCid:PMC7758242
Nozu K, Sako M, Tanaka S, Kano Y, Ohwada Y, Morohashi T et al. (2024). Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial). Clin Exp Nephrol. 28(4): 337-348. https://doi.org/10.1007/s10157-023-02431-0; PMid:38010466 PMCid:PMC10955017
Swart JF, de Roock S, Wulffraat NM. (2013). What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther. 15(3): 213. https://doi.org/10.1186/ar4213; PMid:23731900 PMCid:PMC4060240
Tan J, Renton WD, Whittle SL, Takken T, Johnston RV, Tiller G et al. (2024). Methotrexate for juvenile idiopathic arthritis. Cochrane Database Syst Rev. 2(2): CD003129. https://doi.org/10.1002/14651858.CD003129.pub2; PMid:38334147
Thiele F, Klein A, Windschall D, Hospach A, Foeldvari I, Minden K et al. (2021). Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatol Int. 41(4): 751-762. https://doi.org/10.1007/s00296-020-04774-3; PMid:33590331 PMCid:PMC7952348
Volokha AP, Chernyshova LI. (2010). Rol imunizatsii v zakhysti vid infektsii osib z pervynnymy imunodefitsytamy. Sovremennaya pediatriya. 2: 140-145.
Wang B, Zhang Y, Zhao Z, Ping J, Zhou L, Wang Y, Zhang Y. (2024). Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis. Medicine (Baltimore). 103(18): e38002. https://doi.org/10.1097/MD.0000000000038002; PMid:38701278 PMCid:PMC11062668
Zahran AM, Abdallah AM, Saad K, Osman NS, Youssef MAM, Abdel-Raheem YF et al. (2019). Peripheral Blood B and T Cell Profiles in Children with Active Juvenile Idiopathic Arthritis. Arch Immunol Ther Exp (Warsz). 67(6): 427-432. https://doi.org/10.1007/s00005-019-00560-7; PMid:31535168
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
